Table 1.

Distribution of sociodemographic and clinical characteristics among colorectal cancer patients (n = 6803) aged ≥65 diagnosed from 2005–2007 receiving chemotherapy with versus without bevacizumab (BEV) for metastatic or recurrent disease

Population characteristics	Total % (N = 6803)	No Bev % (N = 4016)	Bev % (N = 2787)
Age at first chemotherapy (years)
65–69	29	29	30
70–74	27	26	27
75–80	24	24	24
80+	20	20	19
Sex
Female	50	50	49
Male	50	50	51
Race
White	84	83	84
Black	8	8	8
Other	8	9	8
AJCC stage at diagnosis**
2	18	23	12
3	44	54	28
4	38	23	60
Revised comorbidity indexa
None	60	59	61
1	28	29	26
2+	12	12	13
History of medical conditionsb
Cardiac disease**
Yes	60	62	56
No	40	38	44
Arterial thromboembolic events (ATEs)*
Yes	5	6	4
No	95	94	96
Congestive heart failure/cardiomyopathy (CHF/CM)
Yes	12	13	11
No	88	87	89

^aCharlson's Index with exclusion of myocardial infarction and congestive heart failure.

^bHistory of general cardiac conditions includes the following diseases: hypertension, arrhythmic disorders, cardiomyopathic disorders, pericardial disorder, aortic wall disorders, and cardiopulmonary arrest.

* and ** indicated a variable with an unadjusted chi-square P value smaller than 0.001 and 0.0001, respectively.